Semaglutide vs tirzepatide: comparing the two leading GLP-1 medications

Semaglutide and tirzepatide are the two most prescribed GLP-1-based weight-management drugs in the US. Both are FDA-approved weekly injections that produce significant weight loss, but they work through different mechanisms, follow different dose-escalation schedules, and carry different price tags. This guide compares them on the dimensions that matter when choosing a telehealth program.

Mechanism: pure GLP-1 vs dual GIP/GLP-1

Semaglutide (Wegovy, Ozempic) is a pure GLP-1 receptor agonist with 94% structural homology to human GLP-1. It activates a single receptor pathway to slow gastric emptying, suppress appetite via the hypothalamus, and modulate insulin and glucagon secretion.

Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway simultaneously. Research shows tirzepatide has stronger affinity for the GIP receptor and requires lower GLP-1 receptor occupancy than semaglutide to achieve comparable effects — approximately 3% receptor occupancy for 5 mg tirzepatide versus 6% for 1 mg semaglutide.

The dual mechanism appears to deliver additional weight loss beyond what GLP-1 receptor activation alone provides, though the exact contribution of GIP agonism is still being studied.

Head-to-head efficacy: SURMOUNT-5 trial

The SURMOUNT-5 trial is the first large head-to-head comparison of these drugs at their maximum weight-management doses. Key results: tirzepatide 15 mg achieved 20.2% mean weight loss versus 13.7% for semaglutide 2.4 mg. In absolute terms, that translates to 22.9 kg (50.5 lb) lost with tirzepatide versus 15.0 kg (33.1 lb) with semaglutide.

Both drugs significantly outperformed placebo in their respective pivotal trials. The STEP 1 trial showed 14.9% mean weight loss with semaglutide over 68 weeks. SURMOUNT-1 showed 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) with tirzepatide over 72 weeks.

Side effect profiles

Both drugs share the same class of GI side effects — nausea, diarrhea, vomiting, constipation. In the head-to-head SURMOUNT-5 trial, nausea rates were comparable at approximately 44% for both drugs. However, tirzepatide showed lower GI-related discontinuation rates (2.7%) compared to semaglutide (5.6%), suggesting better overall tolerability despite similar initial symptom rates.

Both carry the same boxed warning regarding thyroid C-cell tumors and share contraindications (MEN 2, personal/family history of medullary thyroid carcinoma, pregnancy, hypersensitivity). Both require monitoring for pancreatitis, gallbladder disease, and kidney function.

Dose escalation comparison

Semaglutide follows a 4-step escalation over 16 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance). Tirzepatide uses a 5-step escalation over 20+ weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Tirzepatide offers three possible maintenance doses (5, 10, or 15 mg), giving clinicians more flexibility to find the right balance of efficacy and tolerability.

Which drug fits which patient?

• Tirzepatide may be preferred when maximum weight loss is the priority, when a patient has not responded adequately to GLP-1 monotherapy, or when the lower self-pay price point through LillyDirect matters.

• Semaglutide may be preferred when cardiovascular risk reduction is a treatment goal (FDA-approved SELECT indication), when an oral option is desired (Wegovy pill), or when the patient has prior positive experience with semaglutide.

• Insurance coverage may dictate the choice: some plans cover one but not the other, and formulary placement varies significantly.

• Neither drug is superior for every patient. The right choice depends on clinical history, treatment goals, tolerability, insurance coverage, and cost.